Biofrontera Inc. (BFRI) Latest Filing Signal
Cross-checked across multiple AI analysts and grounded in the latest SEC filing.
powered by: earningsVibe.ai
Question:
What is the latest filing signal for Biofrontera Inc.?
Answer:
Based on earningsVibe SuperAnalyst™ synthesis of the latest
10-K, Biofrontera Inc.'s filing signal
turned positive.
earningsVibe SuperAnalyst™ Verdict:
TURNED POSITIVE
Signal Performance — Stock Price Since Filing
30-Day Change
Pending
from filing date
60-Day Change
Pending
from filing date
Underlying analyst views from Perplexity, Gemini, Claude, and ChatGPT
PERPLEXITY
Turned Positive
GEMINI
Turned Positive
CLAUDE
Turned Positive
CHATGPT
Continuing Negative
Unlock the Full Filing Analysis
See full earningsSig™ and risksSig™ analysis across 5,000+ companies
Get Started Free →No credit card required
Question:
What does Biofrontera Inc. actually do?
Answer:
Biofrontera Inc. is a biopharmaceutical company focused on developing, manufacturing, and commercializing dermatological treatments, particularly those utilizing photodynamic therapy (PDT). Its core products, Ameluz and the RhodoLED lamp series, are used to treat actinic keratosis (AK), a common pre-cancerous skin condition. The company sells its products directly to dermatology offices and groups in the United States. Biofrontera aims to improve patient outcomes by expanding Ameluz's label and enhancing its PDT technology. As of December 31, 2025, the company employed 92 individuals across the U.S. and Germany.
Question:
What are Biofrontera Inc.'s revenue drivers?
Answer:
Revenue is generated from the sales of Ameluz and the BF-RhodoLED and RhodoLED XL lamp series. Sales volume and unit pricing are the primary drivers of product revenue.
Cut through noisy SEC filings to find the signal faster
Source-grounded filing intelligence with one-click links back to the filing, so you can move faster and verify everything at the source.
Get Started Free →No credit card required